Insulin Aspart Shortage Update: What Patients Need to Know in 2026

The Insulin Aspart Shortage Isn't Over Yet

If you depend on Insulin Aspart to manage your diabetes, you already know how difficult the past year has been. Shortages that started in 2024 have continued into 2026, leaving patients scrambling to find their mealtime insulin at pharmacies across the country.

This article gives you the latest update on the Insulin Aspart shortage — what's happening, why it's happening, how much the medication costs right now, and exactly what you can do to make sure you don't go without your insulin.

Is Insulin Aspart Still in Shortage in 2026?

Yes. As of early 2026, Insulin Aspart remains on the American Society of Health-System Pharmacists (ASHP) drug shortage list. The shortage primarily affects:

• Fiasp FlexTouch pens — the faster-acting Insulin Aspart formulation in prefilled pen form has been in shortage since 2024
• Fiasp vials — manufacturing delays have caused intermittent supply issues
• NovoLog vials and pens — while more consistently available than Fiasp, some regions are experiencing spot shortages

The situation varies by region and pharmacy. Some patients find NovoLog readily available at one pharmacy while the next one is completely out. This inconsistency makes the shortage especially frustrating to navigate.

Why Is Insulin Aspart Hard to Find?

Several factors are driving the current shortage:

Manufacturing Delays

Novo Nordisk, the manufacturer of both NovoLog and Fiasp, has faced ongoing production challenges. The company has acknowledged that manufacturing delays are affecting the supply of certain Insulin Aspart formulations, particularly Fiasp products. These delays have persisted for over a year.

Discontinuation of the Unbranded Generic

In a move that caught many patients off guard, Novo Nordisk discontinued its unbranded biologic Insulin Aspart on December 31, 2025. This was the more affordable authorized generic version that many patients — especially those without insurance or with high deductibles — relied on. Its removal has reduced overall supply and increased demand for brand-name products.

Supply Chain Complexity

Insulin is a biologic product that requires specialized manufacturing, cold-chain storage, and careful distribution. Unlike simple pills, insulin can't be quickly ramped up in production. Supply chain disruptions anywhere along the line can create shortages that take months to resolve.

Growing Demand

With over 38 million Americans living with diabetes and the number rising each year, demand for insulin products continues to grow. When supply is already strained, even small increases in demand can create noticeable shortages.

For a deeper dive into why finding this medication is difficult, read Why Is Insulin Aspart So Hard to Find?

How Much Does Insulin Aspart Cost in 2026?

The cost of Insulin Aspart depends on your insurance status and which formulation you need:

Brand NovoLog

• Retail price: $130-$350 per vial or pen pack without insurance
• With GoodRx coupon: As low as $74 for generic Insulin Aspart
• With Novo Nordisk savings card: As little as $35/month for eligible patients with commercial insurance (covers up to 3 vials or 2 pen packs)

Medicare Patients

Under the Inflation Reduction Act, Medicare Part D patients pay no more than $35/month for covered insulin products, including Insulin Aspart. There is no deductible for insulin under Medicare Part D.

Savings Tip

Novo Nordisk cut the list price of NovoLog by 75% effective January 1, 2024. If you haven't checked prices recently, you may be pleasantly surprised. For a complete breakdown of savings options, see our guide on how to save money on Insulin Aspart.

New Options in 2026

The insulin landscape is slowly improving. Here are some developments worth knowing about:

Biosimilar Insulin Aspart Products

Biosimilar versions of Insulin Aspart — including Kirsty and Trurapi — have received regulatory approval in some markets. As these products become more widely available, they could help ease supply constraints and drive prices down further.

Alternative Rapid-Acting Insulins

If Insulin Aspart is unavailable, several alternatives may work for you:

• Insulin Lispro (Humalog) — the most common substitute, available as brand and generic
• Insulin Glulisine (Apidra) — another rapid-acting option
• Admelog — a biosimilar to Humalog, often more affordable

Learn more in our article on alternatives to Insulin Aspart.

Expanded Access Programs

Novo Nordisk's Patient Assistance Program (PAP) through NovoCare continues to provide free insulin to eligible uninsured or underinsured patients. The application is available at novocare.com with no registration fee.

How to Find Insulin Aspart in Stock Right Now

Here's your action plan if you need Insulin Aspart today:

1. Search on Medfinder — check real-time pharmacy availability by zip code
2. Call independent pharmacies — they often have stock when chains don't
3. Ask about delivery schedules — pharmacies get shipments on specific days, usually early in the week
4. Set up auto-refill — your pharmacy can reserve your supply as soon as it arrives
5. Talk to your doctor — if you can't find Insulin Aspart, ask about switching to an available alternative

For more detailed tips, read our guide on how to find Insulin Aspart in stock near you.

Final Thoughts

The Insulin Aspart shortage in 2026 is a real challenge, but you have more options and resources than you might think. Stay informed, be proactive about refills, and don't hesitate to reach out to your doctor or use tools like Medfinder to find what you need.

If you're a healthcare provider looking for clinical guidance on this shortage, see our provider-focused update: Insulin Aspart Shortage: What Providers and Prescribers Need to Know in 2026.

Your diabetes management matters — and no shortage should stand in the way of getting the care you need.